About
About CStone Pharmaceuticals
CStone Pharmaceuticals, a biopharmaceutical company, researches and develops anti-cancer therapies to address the unmet medical needs of cancer patients in Mainland China and internationally. The company offers CEJEMLY (sugemalimab), a monoclonal antibody against programmed death (PD) ligand 1 for the treatment of non-small cell lung cancer (NSCLC), gastric adenocarcinoma/gastroesophageal junction adenocarcinoma, esophageal squamous cell carcinoma, and relapsed or refractory natural killer/T cell lymphoma; GAVRETO (pralsetinib), a RET inhibitor to treat patients with advanced or metastatic RET-mutant medullary and RET fusion-positive thyroid cancers, as well as NSCLC and multiple tumors; and AYVAKIT (avapritinib), a KIT/PDGFRA inhibitor, has been approved by the China NMPA for the treatment of adults with unresectable or metastatic GIST harboring a PDGFRA exon 18 mutation, including PDGFRA D842V mutations. It has strategic partnerships with Pfizer, Sanofi, Hengrui, 3SBio Inc., Allist, Ewopharma, Pharmalink, SteinCares, and Gentili. CStone Pharmaceuticals was incorporated in 2015 and is headquartered in Suzhou, China.
Visit company website
5 years, 5 months ago
CStone Pharmaceuticals is currently in a long term uptrend where the price is trading 42.3% above its 200 day moving average.
From a valuation standpoint, the stock is 92.5% cheaper than other stocks from the Healthcare sector with a price to sales ratio of 8.4.
Its net income has increased by 48.7% to $-550M since the same quarter in the previous year.
Finally, its free cash flow grew by 5.6% to $-330M since the same quarter in the previous year.
Based on the above factors, CStone Pharmaceuticals gets an overall score of 4/5.